Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average rating of “Hold” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.24.

ZNTL has been the topic of a number of research reports. Wells Fargo & Company cut their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. UBS Group dropped their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. HC Wainwright reduced their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Finally, Guggenheim lowered their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th.

Zentalis Pharmaceuticals Stock Down 5.7 %

Shares of ZNTL opened at $1.82 on Friday. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $16.27. The company has a 50 day moving average of $2.33 and a two-hundred day moving average of $3.00. The company has a market cap of $129.70 million, a price-to-earnings ratio of -0.73 and a beta of 1.75.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was purchased at an average price of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in ZNTL. Voya Investment Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 14.1% during the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock valued at $173,000 after purchasing an additional 7,058 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock worth $105,000 after acquiring an additional 7,305 shares during the period. Carson Advisory Inc. lifted its holdings in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock valued at $90,000 after purchasing an additional 8,800 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $37,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.